Anzeige
Mehr »
Montag, 13.10.2025 - Börsentäglich über 12.000 News
Der Lithium Markt ist zurück - und Simon Clarke ist mit dabei!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40PJ7 | ISIN: US68232V8845 | Ticker-Symbol: 0T20
NASDAQ
10.10.25 | 21:38
3,010 US-Dollar
-3,83 % -0,120
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
TRAWS PHARMA INC Chart 1 Jahr
5-Tage-Chart
TRAWS PHARMA INC 5-Tage-Chart

Aktuelle News zur TRAWS PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
06.10.Traws Pharma appoints John Leaman to board, removes interim tags from execs1
06.10.Traws Pharma, Inc.: Traws Pharma Adds John Leaman, MD, as Independent Director and Formalizes Appointments of Two Key Executives145NEWTOWN, Pa., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing novel therapies...
► Artikel lesen
06.10.Traws Pharma, Inc. - 8-K, Current Report2
12.09.Traws Pharma, Inc. - 8-K, Current Report3
TRAWS PHARMA Aktie jetzt für 0€ handeln
18.08.Traws Pharma begins Phase 2 trials for ritonavir-free COVID treatment2
18.08.Traws Pharma, Inc.: Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025275Non-inferiority trial to assess safety and efficacy, including rates of disease rebound and incidence of Long COVID development of ratutrelvir, a ritonavir-free treatment, compared to PAXLOVID® Separate...
► Artikel lesen
14.08.Traws Pharma GAAP EPS of -$0.11, revenue of $2.73M2
14.08.Traws Pharma, Inc.: Traws Pharma Reports Second Quarter 2025 Results and Business Highlights878Advancing novel programs for respiratory viruses that pose pandemic threats or risk of serious illness, including SARS CoV2 (ratutrelvir) and influenza (Tivoxavir marboxil, TXM) Prioritization of...
► Artikel lesen
14.08.Traws Pharma, Inc. - 8-K, Current Report2
14.08.Traws Pharma, Inc. - 10-Q, Quarterly Report1
08.08.Traws Pharma, Inc.: Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 20253
03.07.Traws Pharma kündigt Wechsel des Finanzvorstands an16
30.06.Traws Pharma advances clinical trials for influenza and COVID treatments3
30.06.Traws Pharma advances antiviral pipeline with multiple regulatory submissions1
30.06.Traws Pharma, Inc.: Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions368Phase 2 protocol submitted to HREC to evaluate tivoxavir marboxil (TXM) in a combined seasonal and bird flu study in the Southern Hemisphere Briefing documents submitted to FDA for a Type D meeting...
► Artikel lesen
30.06.Traws Pharma, Inc. - 8-K, Current Report1
03.06.Traws Pharma Stock Soars 40% On Positive Clinical Data For Oncology Asset-
03.06.Traws Pharma, Inc.: Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib4
03.06.Traws Pharma, Inc. - 8-K, Current Report-
27.05.Traws Pharma, Inc.: Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness423NEWTOWN, Pa., May 27, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing novel therapies to...
► Artikel lesen
Weiter >>
33 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1